Stay updated on Pembrolizumab Combo in Cisplatin-Ineligible UC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Cisplatin-Ineligible UC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Cisplatin-Ineligible UC Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check21 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed study purpose and inclusion/exclusion criteria for a clinical trial on urothelial cancer, while retaining key information about the study's unblinding process and collaborators.SummaryDifference14%
- Check28 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check36 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check86 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to Pembrolizumab Combo in Cisplatin-Ineligible UC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Cisplatin-Ineligible UC Clinical Trial page.